Learn More
PURPOSE We determine the efficacy and tolerability of bicalutamide as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with clinically localized or locally(More)
The therapeutic index of several anticancer agents may be improved by replacing rapid infusion/bolus injection schedules with prolonged continuous infusion regimens. Admixtures of 5-fluorouracil(More)
Trial 24 is one of three placebo-controlled trials within the ongoing bicalutamide (‘Casodex’†) Early Prostate Cancer (EPC) programme evaluating bicalutamide 150 mg/day in addition to radical(More)
Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy,(More)